128 related articles for article (PubMed ID: 32704091)
1. CTLA4Ig-primed donor lymphocyte infusions following haploidentical transplantation improve outcome with a distinct pattern of early immune reconstitution as compared to conventional donor lymphocyte infusions in advanced hematological malignancies.
Jaiswal SR; Bhakuni P; Bhagawati G; Aiyer HM; Soni M; Sharma N; Jaiswal RR; Chakrabarti A; Chakrabarti S
Bone Marrow Transplant; 2021 Jan; 56(1):185-194. PubMed ID: 32704091
[TBL] [Abstract][Full Text] [Related]
2. Early and Sustained Expansion of Adaptive Natural Killer Cells Following Haploidentical Transplantation and CTLA4Ig-Primed Donor Lymphocyte Infusions Dissociate Graft-versus-Leukemia and Graft-versus-Host Effects.
Jaiswal SR; Chakraborty S; Lakhchaura R; Shashi P; Mehta A; Soni M; Chakrabarti S
Transplant Cell Ther; 2021 Feb; 27(2):144-151. PubMed ID: 33830023
[TBL] [Abstract][Full Text] [Related]
3. CTLA4Ig Primed Donor Lymphocyte Infusion: A Novel Approach to Immunotherapy after Haploidentical Transplantation for Advanced Leukemia.
Jaiswal SR; Bhakuni P; Joy A; Kaushal S; Chakrabarti A; Chakrabarti S
Biol Blood Marrow Transplant; 2019 Apr; 25(4):673-682. PubMed ID: 30610925
[TBL] [Abstract][Full Text] [Related]
4. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study.
Jaiswal SR; Zaman S; Nedunchezhian M; Chakrabarti A; Bhakuni P; Ahmed M; Sharma K; Rawat S; O'donnell P; Chakrabarti S
Cytotherapy; 2017 Apr; 19(4):531-542. PubMed ID: 28131632
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cell-based immunotherapy with CTLA4Ig-primed donor lymphocytes following haploidentical transplantation.
Jaiswal SR; Chakrabarti S
Immunotherapy; 2019 Oct; 11(14):1221-1230. PubMed ID: 31478424
[TBL] [Abstract][Full Text] [Related]
6. Haploidentical Stem Cell Transplantation in Children With Hematological Malignancies Using αβ
Diaz MA; Zubicaray J; Molina B; Abad L; Castillo A; Sebastian E; Galvez E; Ruiz J; Vicario JL; Ramirez M; Sevilla J; González-Vicent M
Front Immunol; 2019; 10():2504. PubMed ID: 31736949
[TBL] [Abstract][Full Text] [Related]
7. CTLA4Ig-based reduced intensity conditioning and donor lymphocyte infusions for haploidentical transplantation in refractory aggressive B-cell lymphoma relapsing after an autograft: Early results from a pilot study.
Jaiswal SR; Aiyer HM; Rawat G; Gera A; Chakrabarti S
Exp Hematol; 2019 Sep; 77():26-35.e1. PubMed ID: 31449833
[TBL] [Abstract][Full Text] [Related]
8. CTLA4Ig in an Extended Schedule along with Sirolimus Improves Outcome with a Distinct Pattern of Immune Reconstitution Following Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation for Hemoglobinopathies.
Jaiswal SR; Bhakuni P; Aiyer HM; Soni M; Bansal S; Chakrabarti S
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1469-1476. PubMed ID: 32428732
[TBL] [Abstract][Full Text] [Related]
9. Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor-Mobilized Donor Lymphocyte Infusions.
Jaiswal SR; Zaman S; Chakrabarti A; Sen S; Mukherjee S; Bhargava S; Ray K; O'Donnell PV; Chakrabarti S
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1867-1873. PubMed ID: 27470289
[TBL] [Abstract][Full Text] [Related]
10. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
[TBL] [Abstract][Full Text] [Related]
11. Alterations in NKG2A and NKG2C Subsets of Natural Killer Cells Following Epstein-Barr Virus Reactivation in CTLA4Ig-based Haploidentical Transplantation Is Associated With Increased Chronic Graft-Versus-Host Disease.
Jaiswal SR; Bhakuni P; Bhagwati G; Aiyar HM; Chakrabarti A; Chakrabarti S
Transplantation; 2020 Jan; 104(1):e23-e30. PubMed ID: 31478993
[TBL] [Abstract][Full Text] [Related]
12. Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy.
Goldsmith SR; Slade M; DiPersio JF; Westervelt P; Schroeder MA; Gao F; Romee R
Bone Marrow Transplant; 2017 Dec; 52(12):1623-1628. PubMed ID: 29035393
[TBL] [Abstract][Full Text] [Related]
13. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
[TBL] [Abstract][Full Text] [Related]
14. The early expansion of anergic NKG2A
Roberto A; Di Vito C; Zaghi E; Mazza EMC; Capucetti A; Calvi M; Tentorio P; Zanon V; Sarina B; Mariotti J; Bramanti S; Tenedini E; Tagliafico E; Bicciato S; Santoro A; Roederer M; Marcenaro E; Castagna L; Lugli E; Mavilio D
Haematologica; 2018 Aug; 103(8):1390-1402. PubMed ID: 29700172
[TBL] [Abstract][Full Text] [Related]
15. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
16. Donor lymphocyte infusion and methotrexate for immune recovery after T-cell depleted haploidentical transplantation.
Gilman AL; Leung W; Cowan MJ; Cannon M; Epstein S; Barnhart C; Shah K; Hyland M; Fukes T; Ivanova A
Am J Hematol; 2018 Feb; 93(2):169-178. PubMed ID: 29047161
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.
Soiffer RJ; Alyea EP; Hochberg E; Wu C; Canning C; Parikh B; Zahrieh D; Webb I; Antin J; Ritz J
Biol Blood Marrow Transplant; 2002; 8(11):625-32. PubMed ID: 12463482
[TBL] [Abstract][Full Text] [Related]
20. Innate Immune Responses in the Outcome of Haploidentical Hematopoietic Stem Cell Transplantation to Cure Hematologic Malignancies.
Zaghi E; Calvi M; Di Vito C; Mavilio D
Front Immunol; 2019; 10():2794. PubMed ID: 31849972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
